PC(o-16:0/20:4(8Z,11Z,14Z,17Z))

Metabolite details

Identifier

SOUZQPFUXRVDGK-KCTKZSJBSA-N

InChI Key

SOUZQPFUXRVDGK-KCTKZSJBSA-N

IUPAC name

Preferred name

PC(o-16:0/20:4(8Z,11Z,14Z,17Z))

INN name

—

Synonym

(2-{[(2R)-3-(hexadecyloxy)-2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyloxy]propyl phosphonato]oxy}ethyl)trimethylazanium

ChEBI

CHEBI:89903

Reactome pathways

• No Reactome pathways listed for this metabolite.

Observed in studies

• Large-Scale Plasma Analysis Revealed New Mechanisms and Molecules Associated with the Host Response to SARS-CoV-2.
• Physiological extremes of the human blood metabolome: A metabolomics analysis of highly glycolytic, oxidative, and anabolic athletes
• A multi-omics approach to study peroxisome proliferator-activated receptor mediated regulation of lipid metabolism in Atlantic cod (Gadus morhua)
• Metabolic Dynamics of In Vitro CD8+ T Cell Activation.
• Metabolic characterization of the natural progression of chronic hepatitis B (Lipid assays).
• Mechanical force promotes dimethylarginine dimethylaminohydrolase 1-mediated hydrolysis of the metabolite asymmetric dimethylarginine to enhance bone formation
• Novel Potential Diagnostic Serum Biomarkers of Metabolomics in Osteoarticular Tuberculosis Patients: A Preliminary Study
• Dysregulation of lipid metabolism and pathological inflammation in patients with COVID-19

Observed in differential profiles

• non_COVID_19_healthy_vs_non_critical_COVID_19
• Control_Baseline_vs_Control_Post-Exercise
• Control_Plasma_vs_WY-14,643_Plasma
• G3_Experimental_Sample_0h_vs_G11_Experimental_Sample_96h
• Control_vs_Immune_Tolerant
• Control_vs_Immune_Tolerant
• Control_vs_Immune_Tolerant
• Control_vs_Exercise
• Healthy_Control_vs_Osteoarticular_Tuberculosis
• Mild_vs_Severe